Brexafemme is a recently approved drug for vaginal yeast infection; the first non-azole treatment. The drug’s sponsor, Scynexis, has made progress in the commercial market, facilitating access. But payer pricing and reimbursement challenges remain.
Brexafemme, New Treatment For Vaginal Yeast Infection, Faces Considerable Pricing And Reimbursement Challenges
